CELYAD ONCOLOGY (CYAD.BR) Stock Price, Forecast & Analysis
Europe - Euronext Brussels - EBR:CYAD - BE0974260896 - Common Stock
CYAD.BR Key Statistics, Chart & Performance
The current stock price of CYAD.BR is 0.17 EUR. In the past month the price decreased by -12.6%. In the past year, price decreased by -75.07%.
CYAD.BR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 67.74 | 44.08B | ||
| ARGX.BR | ARGENX SE | 67.81 | 44.13B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 19.56B | ||
| 2X1.DE | ABIVAX SA | N/A | 9.39B | ||
| ABVX.PA | ABIVAX SA | N/A | 9.37B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.85B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.85B | ||
| NANO.PA | NANOBIOTIX | N/A | 940.20M | ||
| 5CV.DE | CUREVAC NV | 6.24 | 815.12M | ||
| IVA.PA | INVENTIVA SA | N/A | 753.57M | ||
| PHIL.MI | PHILOGEN SPA | 20.44 | 681.29M | ||
| FYB.DE | FORMYCON AG | N/A | 452.35M |
Related stock screener links
About CYAD.BR
Company Profile
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 12 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
Company Info
CELYAD ONCOLOGY
Rue Andre Dumont 9
Mont-Saint-Guibert BRABANT-WALLON BE
Employees: 18
Phone: 3210394100
CELYAD ONCOLOGY / CYAD.BR FAQ
What does CELYAD ONCOLOGY do?
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 12 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
What is the current price of CYAD stock?
The current stock price of CYAD.BR is 0.17 EUR.
Does CYAD stock pay dividends?
CYAD.BR does not pay a dividend.
How is the ChartMill rating for CELYAD ONCOLOGY?
CYAD.BR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of CELYAD ONCOLOGY (CYAD.BR)?
CELYAD ONCOLOGY (CYAD.BR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.16).
Who owns CELYAD ONCOLOGY?
You can find the ownership structure of CELYAD ONCOLOGY (CYAD.BR) on the Ownership tab.
CYAD.BR Technical Analysis
CYAD.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CYAD.BR. CYAD.BR has a bad profitability rating. Also its financial health evaluation is rather negative.
CYAD.BR Financial Highlights
Over the last trailing twelve months CYAD.BR reported a non-GAAP Earnings per Share(EPS) of -0.16. The EPS increased by 30.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -113.33% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |